Table 4.
List of MDM2-p53 inhibitors in previous or current clinical trials are listed MDM2 Inhibitors in Clinical Trials [99].
| Compound Developer | Clinical Trial Phase and Status | References |
|---|---|---|
| RO5045337/RG7112 | phase I | [100] |
| MDM2 antagonist | Completed | |
| (Roche) | ||
| RO5503781/RG7388/Idasanutlin | phase I | [101] |
| MDM2 antagonist | Completed | |
| (Roche) | ||
| AMG232 | phase I | [102] |
| MDM2 antagonist | Completed | |
| (Amgen) | ||
| CGM097 | phase I | [103] |
| MDM2 antagonist | Ongoing but not recruiting | |
| (Novartis) | ||
| DS-3032b/Benzodiazepinedione | phase I | [104] |
| MDM2 antagonist | Recruiting participants | |
| (Daiichi Sankyo) | ||
| SAR405838 | phase I | [105] |
| MDM2 antagonist | Completed | |
| (Sanofi S.A.) | ||
| MK-8242/SCH 900242 | phase I | [106] |
| MDM2 antagonist | Terminated | |
| (Merck) | ||
| ALRN-6924 | Phase I/2a | [94] |
| MDM2/MDMX dual antagonist | Ongoing recruiting | |
| (Aileron Therapeutics) |